These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


109 related items for PubMed ID: 770514

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effects of papaverine in tardive dyskinesia.
    Gardos G, Granacher RP, Cole JO, Sniffin C.
    Prog Neuropsychopharmacol; 1979; 3(5-6):543-50. PubMed ID: 401005
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC.
    Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tardive dyskinesia.
    Clyne KE, Juhl R.
    Am J Hosp Pharm; 1976 May; 33(5):481-6. PubMed ID: 1274963
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD.
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial.
    Gerlach J, Thorsen K, Munkvad I.
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar; 8(2):51-6. PubMed ID: 788002
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
    Kazamatsuri H, Chien C, Cole JO.
    Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831
    [No Abstract] [Full Text] [Related]

  • 13. Long-term effects of tetrabenazine in hyperkinetic movement disorders.
    Jankovic J, Beach J.
    Neurology; 1997 Feb; 48(2):358-62. PubMed ID: 9040721
    [Abstract] [Full Text] [Related]

  • 14. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study.
    Bazo AJ.
    J Am Geriatr Soc; 1973 Feb; 21(2):63-71. PubMed ID: 4631704
    [No Abstract] [Full Text] [Related]

  • 15. Tetrabenazine and movement disorders.
    Asher SW, Aminoff MJ.
    Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 18. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
    Munetz MR, Cornes CL.
    J Clin Psychopharmacol; 1983 Dec 01; 3(6):343-50. PubMed ID: 6139392
    [Abstract] [Full Text] [Related]

  • 19. Effect of cholinergic and anticholinergic agents on tardive dyskinesia.
    Klawans HL, Rubovits R.
    J Neurol Neurosurg Psychiatry; 1974 Aug 01; 37(8):941-7. PubMed ID: 4418481
    [Abstract] [Full Text] [Related]

  • 20. Tardive dyskinesia treated with pimozide.
    Claveria LE, Teychenne PF, Calne DB, Haskayne L, Petrie A, Pallis CA, Lodge-Patch IC.
    J Neurol Sci; 1975 Apr 01; 24(4):393-401. PubMed ID: 235013
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.